TherapeuticsMD, Inc. 8-K

What Happened

• On May 12, 2026, TherapeuticsMD, Inc. (a Nevada corporation) announced and furnished a press release reporting its first quarter 2026 financial results for the quarter ended March 31, 2026. The press release was filed as Exhibit 99.1 to the Current Report on Form 8‑K (Items 2.02 and 7.01).

Key Details

• Date of disclosure: May 12, 2026.
• Reporting period: Quarter ended March 31, 2026 (Q1 2026).
• Press release titled “TherapeuticsMD Announces First Quarter 2026 Financial Results” is attached as Exhibit 99.1 to the 8‑K.
• The 8‑K reports under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure).

Why It Matters

• This 8‑K is the company’s official public disclosure of its Q1 2026 earnings and operating results; investors should review the furnished press release for specific metrics such as revenue, net income/loss, and cash position.
• Quarterly results can affect valuation and near‑term trading; the press release provides the first snapshot of performance for the period and may be followed by more detailed filings (e.g., Form 10‑Q).
• Retail investors should read the full Exhibit 99.1 press release and look for subsequent SEC filings or company guidance for a complete view before making investment decisions.